Accessibility Menu
Cellectar Biosciences logo

Cellectar Biosciences(NASDAQ) CLRB

Current Price$2.51
Market Cap$20.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-99%
1 Year-50%
1 Month-10%
Cellectar Biosciences last closing stock price
MetricPriceDate
Last closeUSD 2.522026-07-20
Cellectar Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.18%USD 2.632026-07-13
1 month-9.68%USD 2.792026-06-18
3 month-11.27%USD 2.842026-04-21
Year to date-14.58%USD 2.952025-12-31
1 year-49.5%USD 4.992025-07-18
3 year-95.94%USD 62.102023-07-21
5 year-99.26%USD 339.002021-07-21
Since inception-100%USD 1,799,964.002011-04-11

Cellectar Biosciences Financials at a Glance

Market Cap

$20.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$20.84M

EPS (TTM)

-$7.37

P/E Ratio

-0.34

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Price

$2.51

Volume

6,858.818

Open

$2.53

Previous Close

$2.52

Daily Range

$2.52 - $2.63

52-Week Range

$2.20 - $6.52

Estimated Earnings Date

Aug 13, 2026

CLRB News

Foolcom-Featured.png

Cellectar Cuts Q2 Losses and Expenses

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cellectar Biosciences

Cellectar develops drugs to treat cancer, focusing on hard-to-treat cases. Its main products aim to deliver targeted therapy, reducing harm to healthy cells. These treatments are designed for patients with limited options, such as those with rare or recurring cancers.

Lab Bench to Bedside: What Cellectar Makes

  • Iopofosine I 131 (CLR 131): A targeted radiotherapy drug in clinical trials for blood cancers and pediatric tumors. (0% of revenue; pre-commercial)
  • CLR 125: A radiotherapy candidate for triple negative breast cancer, in early-stage studies. (0% of revenue)
  • CLR 225: A preclinical radiotherapy drug for solid tumors, not yet in human trials. (0% of revenue)
  • CLR 1900: A chemotherapy drug in preclinical development for solid tumors. (0% of revenue)
  • Collaborative Programs: Joint research with Avicenna Oncology, Orano Med, IntoCell, and LegoChemBio to expand the drug pipeline. (0% of revenue)

Growth Spurts and Science Sprints

  • Launched multiple clinical trials for iopofosine I 131 from 2022 to 2025.
  • Formed partnerships with Avicenna Oncology, Orano Med, IntoCell, and LegoChemBio.
  • Expanded pipeline with new drug candidates and preclinical programs.
  • Completed a 1:30 reverse stock split in June 2025 to maintain NASDAQ listing.
  • Raised $6.9 million in a public offering in July 2025.

Why Cellectar Catches the Eye

Cellectar uses a unique drug delivery platform that targets cancer cell membranes, not just surface markers. This approach allows for a wide range of cancer drugs to be delivered more precisely. The company’s regulatory designations may speed up development and approval for its lead products.

Five Things You Need to Know

  • No product revenue reported for Q2 2025 or prior periods.
  • Operating expenses were $6.0 million in Q2 2025, a 55.9% improvement year-on-year.
  • Net loss was $5.4 million in Q2 2025, 492.6% higher (more negative) compared to Q2 2024.
  • Cash and cash equivalents were $11.0 million as of June 30, 2025.
  • Company faces going concern risk if it cannot secure more funding by Q2 2026.

Bottom Line

Cellectar remains focused on developing targeted cancer therapies, with no commercial sales yet. Its future depends on clinical progress and securing additional funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

11

CEO

James V. Caruso

Website

www.cellectar.com

Headquarters

Florham Park, NJ 07932, US

CLRB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-264.79%

Return on Capital

-222.48%

Return on Assets

-187.42%

Earnings Yield

-2.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.99M

Volume

6.86K

Avg. Volume

1.07M

Financials (TTM)

Gross Profit

$110.02K

Operating Income

-$22.37M

EBITDA

-$20.79M

Operating Cash Flow

-$18.58M

Capital Expenditure

-$9.26K

Free Cash Flow

-$18.59M

Cash & ST Invst.

$8.35M

Total Debt

$1.53M

Cellectar Biosciences Performance Analysis

Cellectar Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Cellectar Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Cellectar Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -135.183.7%
20232023-12-31USD -104.99-22.3%
20242024-12-31USD -41.89-60.1%
20252025-12-31USD -8.35-80.1%
Cellectar Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3021.2%
Q32025-09-3058.4%
Q42025-12-3111.3%
Q12026-03-31-6.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$110.02K

N/A

Gross Margin

0.00%

N/A

Market Cap

$20.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.83M

N/A

Employees

11

N/A

Net Income

-$5.65M

+14.4%

EBITDA

-$5.76M

+12.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$8.35M

-40.0%

Total Debt

$1.53M

+222.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.53M

+295.9%

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.87%

N/A

Return on Invested Capital

-3.58%

N/A

Free Cash Flow

-$4.85M

+48.3%

Operating Cash Flow

-$4.85M

+48.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNSESensei Biotherapeutics, Inc.
$13.85-22.28%
MRKRMarker Therapeutics, Inc.
$1.32+2.73%
CINGCingulate Inc.
$4.74+3.95%
BOLTBolt Biotherapeutics, Inc.
$4.29-4.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
VIVKVivakor
$5.49+2.17%
UTZUtz Brands
$14.12+0.89%
AALAmerican Airlines Group
$15.28+0.01%
SOFISoFi Technologies
$17.44+0.02%

Questions About CLRB

What is the current price of Cellectar Biosciences?

Cellectar Biosciences is trading at $2.61 per share.

What is the 52-week range for Cellectar Biosciences?

Over the past 52 weeks, Cellectar Biosciences has traded between $2.20 and $6.52.

How much debt does Cellectar Biosciences have?

As of the most recent reporting period, Cellectar Biosciences reported total debt of $1.53M.

How much cash does Cellectar Biosciences have on hand?

Cellectar Biosciences reported $8.35M in cash and cash equivalents in its most recent financial results.

What is Cellectar Biosciences’s dividend yield?

Cellectar Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services